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doi:10.1016/j.jtcvs.2007.03.013bjective: Preoperative exposure to clopidogrel and aspirin significantly increases
ostoperative bleeding in patients undergoing on-pump coronary artery bypass graft
urgery. Off-pump coronary bypass grafting has been proposed as an alternative
echnique to attenuate postoperative bleeding associated with clopidogrel. This
tudy aimed to determine the effects of aspirin and clopidogrel therapy on periop-
rative blood loss and blood transfusion requirements in off-pump coronary artery
ypass grafting.
ethods: One hundred six patients scheduled for off-pump coronary artery bypass
rafting were divided into three groups: aspirin and clopidogrel discontinued more
han 6 days before surgery (group 1, n 35), aspirin and clopidogrel continued until
to 5 days before surgery (group 2, n 51), and both medications continued within
days of surgery (group 3, n  20). Thromboelastographic tracings were analyzed
efore induction of anesthesia. Routine coagulation profiles were measured before
nd after surgery. A cell salvage device was used during surgery and salvaged blood
as reinfused. Chest tube drainage and blood transfusion requirement were re-
orded postoperatively.
esults: Patient characteristics, operative data, and thromboelastographic tracings
ere similar among the groups. There were significant decreases in hematocrit level
nd platelet count and prolongation in prothrombin time postoperatively in all
roups without any intergroup differences. The amounts of perioperative blood loss
nd blood transfusion required were all similar among the groups.
onclusion: Preoperative clopidogrel and aspirin exposure even within 2 days of
urgery does not increase perioperative blood loss and blood transfusion require-
ents in patients undergoing elective off-pump coronary artery bypass grafting.
lopidogrel is an irreversible adenosine 5= disphosphate receptor antagonis
that provides potent antiaggregant effect on platelets.1,2 The enhanced
antiplatelet therapy provided by clopidogrel has led to its use in combination
ith aspirin as the gold standard for prevention of intracoronary stent thrombo3,4
n addition, favorable results regarding prevention of recurrent ischemic events
eading to reduced risk of cardiovascular morbidity and mortality have been dem-
nstrated by large multicenter trials in patients with coronary artery occlusive
isease receiving clopidogrel.5,6
As the indications for clopidogrel expand, an increasing percentage of patients
eferred for coronary artery bypass graft surgery (CABG) are subjected to irrevers-
ble platelet inhibition. In conjunction, a number of studies have demonstrated
ncreased procedural bleeding, blood transfusion requirement, and the need for
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A
CDurgical re-exploration related to clopidogrel in patients
ndergoing conventional on-pump CABG,7-10 prompting
uggestions to delay the operation or transfuse platelets
erioperatively. However, caution should be exercised,
eighing the risk of postoperative blood loss and its sequelae
nd the clinical benefits of sustained antiplatelet therapy in
reventing graft occlusion and ischemic complications.11,12
Off-pump CABG is associated with significantly reduced
ates of postoperative bleeding and blood transfusion re-
uirements, presumably in part because of avoidance of
ardiopulmonary bypass–induced blood component dilution
nd dysfunction.13 Therefore, it has been proposed as 
lternative surgical technique to reduce postoperative bleed-
ng in patients with coronary artery occlusive disease who
ave recent exposure to antiplatelet therapy.14,15 Yet, these
tudies demonstrate conflicting results and were either pre-
iminary or retrospective, lacking statistical power or risk
djustment between the groups.10,16,17
We therefore evaluated the influence of preoperative
ombined aspirin and clopidogrel medication on perioperative
lood loss and blood transfusion requirements in patients un-
ergoing elective off-pump CABG in a prospective trial.
atients and Methods
fter institutional review board approval and surrogate informed
onsent were obtained, patients scheduled for isolated mutivessel
ff-pump CABG between November 2005 and August 2006 were
tudied. Patients undergoing emergency surgery and those with a
istory of previous cardiac surgery, preoperative exposure to war-
arin sodium (Coumadin), platelet glycoprotein IIb/IIIa inhibitors,
r thrombolytics were excluded. Accordingly, a total of 106 pa-
ients were included in the study. The timing of discontinuation of
ntiplatelet medications was at the discretion of the cardiologists
ather than dictated by the protocol.
Patients were divided into three groups according to their
edication history: patients whose aspirin and clopidogrel were
iscontinued more than 6 days before surgery (group 1, n  35),
atients who received a daily oral regimen of 100 mg of aspirin
nd 75 mg of clopidogrel until 3 to 5 days before surgery (group
, n  51), and patients who continued both medications within 2
ays of surgery (group 3, n 20). The subdivisions at 5 and 2 days
ere according to the recent American College of Cardiology/
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
CABG  coronary artery bypass graft
FFP  fresh frozen plasma
ICU  intensive care unit
MI myocardial infarction
pRBCs packed red blood cells
PT  prothrombin time
SD  standard deviationmerican Heart Association recommendation and to the rate of p
0 The Journal of Thoracic and Cardiovascular Surgery ● July 2eplacement of exposed platelets by new platelets, respectively. 18-20
ll other cardiovascular medications except diuretics were contin-
ed until the day of the operation.
All patients received 0.05 to 0.1 mg/kg of morphine intramus-
ularly as premedication 1 hour before the operation. On the
atient’s arrival at the operating room, standard monitoring de-
ices were applied, including a pulmonary arterial catheter (Swan-
anz CCOmbo CCO/SvO2; Edwards Lifesciences, Irvine, Calif),
hich was inserted through the right internal jugular vein before
nduction of anesthesia. Anesthesia was induced with intravenous
idazolam (0.05 mg/kg) and sufentanil (1.5–3.0 g/kg) and was
aintained with sevoflurane (0.8–1.5 vol/100 mL) and continuous
nfusion of sufentanil (0.5–1.5 g · kg1 · min1). Neuromuscular
lockade was achieved by administering rocuronium bromide (0.9
g/kg) and maintained with continuous infusion of vecuronium
romide (1–2 g · kg1 · min1). After induction of anesthesia, a
ransesophageal echocardiography probe was inserted to detect
ewly developing segmental wall motion abnormalities. Isosor-
ide dinitrate 0.5 g · kg1 · min1 was infused in all patients
hroughout the study period. Intravascular volume replacement
as managed with crystalloid and colloid solutions to maintain the
ulmonary capillary wedge pressure between 8 and 16 mm Hg
ccording to the baseline values. Central temperature, as measured
y pulmonary arterial catheter, was maintained between 36°C and
7°C with a warm mattress, forced warm air blanket, and fluid
armer as necessary.
All surgical procedures were performed by one surgeon
hrough a median sternotomy, and the heart was displaced with a
osterior pericardial stitch, large (12  70 cm) gauze swabs, and
issue stabilizer (Octopus Tissue Stabilization System; Medtronic
nc, Minneapolis, Minn). Systemic heparinization during anasto-
oses was achieved with 150 U/kg of porcine heparin with addi-
ional doses to reach the target activated clotting time greater than
00 seconds. On completion of anastomoses, heparin activity was
eutralized with protamine sulfate (0.5 mg/150 U of heparin). A
ell salvage device was used during the operation in all cases and
alvaged blood was reinfused to the patient before the end of the
peration. None of the patients received antifibrinolytics through-
ut the study period. All patients were transferred to the intensive
are unit (ICU) after the operation.
Allogenic packed red blood cells (pRBCs) were transfused
hen the hematocrit level was less than 25% for patients 65 years
f age or older and when the hematocrit level was less than 21%
or patients younger than 65 years of age throughout the study
eriod. Fresh frozen plasma (FFP) was transfused when the post-
perative international normalized ratio was greater than 1.5 with
xcessive bleeding greater than 200 mL/h for 2 consecutive hours.
he criteria for transfusion of platelets were postoperative platelet
ount less than 50,000/mm3 with excessive bleeding greater than
00 mL/h for 2 consecutive hours. Surgical re-exploration was
ndicated when chest tube drainage was greater than 200 mL/h for 6
onsecutive hours or greater than 400 mL during the first hour despite
ormalized activated clotting time and global coagulation status.
Hematocrit level, platelet counts, prothrombin time (PT), and
ctivated partial thromboplastin time (aPTT) were measured 24
ours before and after the operation. Thromboelastographic trac-
ngs were analyzed before induction of anesthesia to detect other
ossibly existing coagulation abnormalities between the groups by
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CDeasuring reaction time (r-time), coagulation time (K-time), clot
ormation rate (-angle), and clot strength (maximal amplitude)
ith a 2-channel coagulation analysis system (TEG model 3000;
aemoscope Corp, Niles, Ill). Total number of units of pRBCs,
FP, and platelets given during the postoperative hospitalization
eriod were recorded, including the number of units given during
he operation and in the ICU postoperatively. Intraoperative blood
oss was recorded as the amount of reinfused salvaged blood by a
ell salvage device. Postoperative blood loss was recorded as the
olume of chest tube drainage measured at 24 hours after surgery
nd the drained blood was not reinfused.
Statistical analyses were performed with SPSS 12.0 (SPSS Inc,
hicago, Ill). All data are expressed as number of patients (per-
entage) or mean  SD. A difference of 250 mL of chest tube
rainage between the groups was taken as clinically significant to
educe 1 unit transfusion of pRBCs. We determined that 20 pa-
ients would be required in each group with 80% power and alpha
evel of .05 to detect a 250-mL difference in postoperative blood
oss among the groups with an SD of 250 mL,21,22 and with th
ame power and alpha level to detect 1 unit of pRBC difference in
ransfusion requirements among the groups in the ICU postoper-
tively with an SD of 1 unit using analysis of variance. Data
etween the groups were compared by the 2 test, Fisher exact test,
r 1-way analysis of variance with post hoc comparison using the
onferroni test as appropriate. Data within the group were com-
ared by the paired t test.
esults
ff-pump CABG could be successfully performed in all
atients, except one conversion to cardiopulmonary bypass
n group 2 owing to development of intractable arrhythmia
uring posterior descending artery grafting. None of the
atients had newly developed segmental wall motion ab-
ormalities and postoperative electrocardiographic changes
ABLE 1. Patient characteristics, operative data, and dura
Group 1 (n  33)
ge (y) 63.8 8.7
ex (M/F) 24/9
eight (cm) 163.2 8.4
eight (kg) 64.5 9.6
ody surface area (m2) 1.7  0.2
reoperative medication
-blockers 23 (70)
ACE inhibitors 22 (66)
Calcium channel blockers 19 (58)
ypertension 17 (52)
iabetes mellitus 12 (36)
reatinine level (mg/dL) 1.2 0.8
peration time (min) 344 67
o. of grafts 3.3 0.7
CU days 2.9 0.7
ostoperative hospital days 12.9 7.0
alues are either mean  SD or number of patients (percentage). ACE, An
ostoperative hospital days, length of postoperative hospitalization period inclu
The Journal of Thoracndicative of myocardial infarction (MI). Hemostatic re-
xploration was performed in 2 patients in group 1, and both
atients had an obvious surgical cause of bleeding. Data for
hese 3 patients were excluded from statistical analysis.
therwise, of the included 103 patients, none required he-
ostatic re-exploration.
There were no significant differences in demographic
nd operative data including history of MI, preoperative
erum creatinine level, left ventricular ejection fraction,
umber of grafts, and operation time among the groups. The
ength of stay in the ICU and total length of postoperative
ospitalization period were also similar among the groups
Table 1).
Preoperative thromboelastographic variables were com-
arable among the groups. There were no significant differ-
nces in hematocrit level, platelet counts, PT, and aPTT
efore and after surgery among the groups. Postoperative
ematocrit level was significantly decreased and PT was
ignificantly prolonged compared with preoperative values
n all three groups (all P values are  .0001). Postoperative
latelet counts were significantly decreased compared with
reoperative values in groups 1 and 2 (both P values are 
0001). Postoperative aPTT was significantly prolonged
ompared with preoperative values in group 3 (P  0.004)
Table 2).
Total amount of fluid infused and urine output during the
peration and first 24 hours in the ICU postoperatively were
imilar between the groups. There were no significant dif-
erences in the amount of re-infused blood salvaged with a
ell salvage device in the operating room and postoperative
lood loss among the groups (Table 3).
of hospital admission
Group 2 (n  50) Group 3 (n  20) P value
61.6  10.3 63.7  8.4 .527
41/9 16/3 .503
160.8  8.4 164.6  7.8 .185
65.7  10.6 65.0  16.2 .884
1.7  0.2 1.8  0.2 .449
38 (76) 15 (79) .720
33 (66) 8 (42) .148
28 (56) 13 (68) .635
27 (54) 13 (68) .554
15 (30) 8 (42) .483
1.1  0.7 1.1  0.3 .727
363  97 348  85 .573
3.4  0.8 3.3  0.9 .818
2.8  0.6 2.7  0.7 .595
11.0  4.1 10.1  2.2 .174
sin converting enzyme; ICU days, length of stay in the intensive care unit;tion
gioten
ding ICU days; P value, intergroup comparison.
ic and Cardiovascular Surgery ● Volume 134, Number 1 61
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A
CDNone of the patients received FFP and platelets during
he operation. Amounts of transfused FFP in the postoper-
tive period were similar among the groups and were 10 units
n 4 patients, 13 units in 4 patients, and 2 units in 1 patient in
roups 1, 2 and 3, respectively. Amounts of transfused platelets
n the postoperative period were also similar among the groups
nd were none in group 1 and 8 units in 1 patient each in
roups 2 and 3. A total of 58 patients received pRBCs during
ABLE 2. Hematologic and coagulation profile
Group 1 (n  33)
ematocrit (%)
Pre 35.9  5.7
Post 25.9  2.5*
rothrombin time (s)
Pre 12.5  2.2
Post 14.5  1.0*
PTT (s)
Pre 44.6  20.9
Post 43.2  9.1
latelet count (103/mm3)
Pre 243  83
Post 171  63
hromboelastography
Reaction time (mm) 26.0 9.6
Clotting time (mm) 10.1 4.1
-angle (°) 41.5 10.1
Maximal amplitude (mm) 44.6 6.0
alues are mean SD. Pre, Preoperative 1 day; Post, 24 hours postoperativ
P  .05 compared with preoperative value.
ABLE 3. Perioperative fluid balance and amount of perio
Group 1 (n  3
luid input (L)
OR 4.4  0.9
ICU24 2.9 1.1
rine output (mL)
OR 1094 658
ICU24 2307 891
lood loss (mL)
OR 265 146
ICU24 756 408
RBC transfusion (units)
OR 0.4  0.5
ICU 0.4 0.7
Total 1.1 1.8
o. of patients transfused with pRBC (%)
OR 13 (39)
ICU 14 (42)
Total 17 (52)
alues are either mean  SD or number of patients (percentage). pRBC, P
n the intensive care unit postoperatively; ICU, during admission in the int
eriod including OR and ICU; P value, intergroup comparison.
2 The Journal of Thoracic and Cardiovascular Surgery ● July 2he entire postoperative hospitalization period, with 23 patients
uring the operation and 40 patients in the ICU. The number of
atients and total amount of transfused pRBCs were similar
mong the groups (Table 3).
iscussion
n this prospective study, continuing clopidogrel and aspirin
ven within 2 days of surgery did not result in increased
roup 2 (n  50) Group 3 (n  20) P value
37.3  5.3 39.4  4.5 .063
24.8  3.3* 24.1  2.7* .092
12.1  1.1 11.4  0.8 .071
14.6  2.5* 15.1  1.6* .772
41.8  16.5 34.7  7.6 .121
41.5  10.1 41.9  8.3* .757
226  79 231  472 .586
150  65 144  382 .206
29.5  8.1 29.8  6.9 .176
11.9  5.3 12.4  3.5 .200
37.0  10.9 33.8  8.5 .056
44.1  8.6 41.9  7.9 .481
PTT, activated partial thromboplastin time; P value, intergroup comparison;
tive blood loss and transfusion
Group 2 (n  50) Group 3 (n  20) P value
5.0  1.7 4.7  1.2 .147
3.1  0.9 3.4  1.0 .569
963  539 827  453 .264
2255  922 2387  780 .857
330  191 323  187 .174
729  485 627  257 .425
0.5  0.5 0.3  0.4 .260
0.7  1.0 0.6  1.0 .512
1.9  0.8 1.6  1.9 .386
24 (48) 5 (26) .255
21 (42) 5 (25) .368
32 (64) 9 (45) .279
d red blood cell; OR, during the operation; ICU24, during the first 24 hours
care unit postoperatively; Total, during the postoperative hospitalizationG
ely; apera
3)
acke
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A
CDmount of perioperative blood loss and blood transfusion
equirement while applying intraoperative blood salvage
echnique and strict transfusion guidelines in patients un-
ergoing elective off-pump CABG.
After the encouraging results of Clopidogrel in Unstable
ngina to prevent Recurrent ischemic Events (CURE)5 and
lopidogrel vs. Aspirin in patients at Risk of Ischemic
vents (CAPRIE)6 trials, which demonstrated reduced ri
f cardiovascular death, MI, and cerebrovascular accident in
atients with acute coronary syndrome, prophylactic anti-
latelet therapy with clopidogrel is being more aggressively
rescribed. Clopidogrel was also superior to aspirin alone
or prevention of post-CABG ischemic events.23 Therefore,
ncreasing numbers of patients with coronary artery occlu-
ive disease are brought to surgery with recent clopidogrel
xposure.
Despite the beneficial effect of combined clopidogrel and
spirin medication, especially in patients with ongoing ische-
ia, concerns have been raised regarding risk of postoper-
tive bleeding and its sequelae in cardiac surgical patients.
ncreased risk of postoperative bleeding, transfusion, and
e-exploration with combined clopidogrel and aspirin in
atients having on-pump CABG has been reported in sev-
ral studies,7-10 although excess bleeding associated wi
lopidogrel predominantly compromised moderate rather
han major bleeding in a recent large-scale randomized
tudy.24
Owing to avoidance of cardiopulmonary bypass–induced
oagulation abnormalities and its association with lower
ate of hemorrhagic sequelae,25 off-pump CABG may hav
role in decreasing postoperative bleeding and its sequelae,
hereby eliminating the need to delay surgery in patients
xposed to clopidogrel.14,15 Indeed, there has been a limit
umber of studies regarding the relationship between recent
lopidogrel and aspirin exposure with postoperative blood loss
n off-pump CABG, and the results are contradictory.10,16,17
ecently, there was a study evaluating the effect of preopera-
ive clopidogrel on the incidence of hemostatic re-exploration,
equirement for blood product transfusion, morbidity, and
ortality in patients undergoing off-pump CABG using a
arge sample size of patients.16 In that study, preoperativ
lopidogrel administration emerged as the single most sig-
ificant predictive factor for hemostatic re-exploration and
lood product transfusion requirements. However, it was a
etrospective study without measuring actual postoperative
lood loss, and the patients who received clopidogrel had a
ower body weight, higher incidence of preoperative MI,
nd more frequent need for urgent revascularization.
eight is an independent predictor of blood, and preoper-
tive MI and urgent surgery are also widely known risk
actors for postoperative blood loss.9,15
Bleeding after CABG can be multifactorial, and along
ith inadequate surgical hemostasis, pre-existing coagula- a
The Journal of Thoracion and platelet abnormalities, potential risk factors include
ge, female gender, weight, diabetes, hypertension, renal
nsufficiency, left ventricular ejection fraction, history of
I, and preoperative hematocrit values.9,10,15,16 To the bes
f our knowledge, this is the first prospective, controlled
tudy with well-matched known risk factors for postopera-
ive blood loss and coagulation profiles including throm-
oelastographic tracings among the groups, demonstrating
he safety of continued antiplatelet therapy in terms of
erioperative blood loss and blood transfusion requirements
n patients undergoing off-pump CABG. Also, this is the
rst study considering the timing of discontinuation of
lopidogrel before off-pump CABG. Re-exploration rate
ended to be higher for those patients undergoing on-pump
ABG within 5 days after the last clopidogrel dose,24,25 and
he American College of Cardiology/American Heart Asso-
iation recommended that clopidogrel should be withheld
or at least 5 days in patients scheduled for elective CABG
urgery.18 While in a study evaluating the safe time inte
f discontinuation of clopidogrel medication before on-
ump CABG, discontinuation 3 days before surgery was not
ssociated with significantly increased postoperative bleed-
ng.20 We divided the patient groups accordingly and co
ot observe any significant differences in the amount of
erioperative blood loss or blood transfusion requirements
mong the groups, suggesting that surgery may not be
elayed on the basis of antiplatelet therapy in patients
cheduled for elective off-pump CABG.
The limitations of this study are as follows. Although this
as a prospective study and the patients’ characteristics
ere similar among the groups, the timing of discontinua-
ion of antiplatelet therapy was at the discretion of the
ardiologists not aware of this study, rather than dictated by
he protocol, and therefore the patients could not be ran-
omized. Also, the surgeon was not blinded to the antiplate-
et regimen. In addition, we did not compare the weight of
he blood-soaked and dry gauzes and tapes applied during
he operations, and the amount of unmeasured intraopera-
ive blood loss might have been greater in groups 2 and 3.
inally, this study may not be sufficiently powered with
egard to amount of postoperative blood loss because the
argest actual SD was larger than the SD we used for sample
ize calculation. However, the P value for intergroup com-
arison of postoperative blood loss was .425 and the mean
nd SD values were actually the lowest in group 3, which
onsists of patients who were exposed to clopidogrel and
spirin within 2 days of surgery. Furthermore, there were no
ignificant differences in the subsequent transfusion require-
ent of pRBC among the groups, especially during the
mmediate postoperative period in the ICU, with enough
tatistical power.
In conclusion, preoperative clopidogrel and aspirin ther-
py did not result in increased perioperative blood loss and
ic and Cardiovascular Surgery ● Volume 134, Number 1 63
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A
CDlood transfusion requirements in patients undergoing elec-
ive off-pump CABG. Therefore, instead of delaying sur-
ery unnecessarily, off-pump CABG may be considered as
n alternative technique in patients receiving potent anti-
latelet therapy. Furthermore, regarding the increased pro-
oagulant activity after off-pump CABG26 and the clinica
enefits of sustained antiplatelet therapy in preventing graft
cclusion and ischemic complications,11,12,23 we suggest
ontinuing appropriate antiplatelet therapy in patients
cheduled for elective off-pump CABG.
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